Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Bluebird Bio (BLUE – Research Report) today and set a price target of $100.00. The company’s shares closed last Monday at $81.00, close to its 52-week low of $79.91.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of 6.0% and a 56.8% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Global Blood Therapeutics, and Fulcrum Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluebird Bio with a $135.20 average price target, which is a 63.3% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Hold rating on the stock with a $85.00 price target.
Based on Bluebird Bio’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $196 million. In comparison, last year the company had a GAAP net loss of $145 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.